PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

New Patient and Physician Voice of the Customer for U.S. Drug Delivery - Frost & Sullivan is seeking partner companies for a new end-user study on preferences and drivers of adoption for various drug delivery technologies in the U.S. pharmaceutical market
New Patient and Physician Voice of the Customer for U.S. Drug Delivery

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2008/07/21 - Frost & Sullivan is seeking partner companies for a new end-user study on preferences and drivers of adoption for various drug delivery technologies in the U.S. pharmaceutical market.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Following successful work in the areas of diabetes, chronic pain, inflammation and neurological disorders, Frost & Sullivan is seeking partner companies for a new end-user study on preferences and drivers of adoption for various drug delivery technologies in the U.S. pharmaceutical market.

Through interviews with both physicians and patients, Frost & Sullivan aims to identify key drivers and obstacles to adoption and utilization of various drug delivery technologies. Additionally, patient feedback will be obtained in terms of awareness, usage, and desired improvements of specific brands as determined by clients.

Frost & Sullivan seeks feedback on areas of interest to the industry for an in-depth look at these issues from respondents. Various new therapeutic areas and treatment settings are being evaluated. The final decision for this new project will be based on market demand and shaped to meet the needs of the industry.

If you are interested in partnering with us, shaping, or obtaining the research for the study U.S. Drug Delivery Voice of the Customer 2008, please send an email to Johanna Haynes, Corporate Communications, at johanna.haynes[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state and country.

“Understanding how patients and prescribers view drug delivery methods as part of treatment is vital to drug developers throughout the industry,” notes Frost & Sullivan Industry Manager Daniel Ruppar. “Especially as companies evaluate new delivery opportunities, understanding how different technologies are viewed may lead to new product pathways not previously considered.”

While there are numerous types of drug delivery technologies available in terms of approved drugs for a disease, physician and patient decision factors are often the primary determinant of drug choice. This can especially impact drugs using device-driven drug delivery, or the success of new first-in-class products with novel delivery approaches.

“Developers that can better understand the drivers and obstacles of adoption and utilization preferences for pharmaceutical drug delivery can develop and refine their technologies to best serve patients and the medical community,” says Ruppar. “This can also drive decision factors for both lifecycle management activities and R&D programs.”

U.S. Drug Delivery Voice of the Customer 2008 is part of ongoing research conducted within the Pharmaceutical and Biotechnology Subscription, which also includes research in the following markets: Contract Research & Manufacturing, Biopharmaceuticals, Specialty Pharmaceuticals, Vaccines and Drug Delivery. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting, and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


New Patient and Physician Voice of the Customer for U.S. Drug Delivery

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Johanna Haynes 
210.247.3870 johanna.haynes[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)